ArticleThe Journal of clinical investigation2012
Targeting PES1 for restoring the ERα/ERβ ratio in breast cancer.
Article in The Journal of clinical investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 24 citations in OpenAlex.
- The functional role of Pescadillo ribosomal biogenesis factor 1 in cancer.Journal of Cancer · 2022Review
- InInternational journal of molecular sciences · 2021Article
- microRNA-1271 impedes the development of prostate cancer by downregulating PES1 and upregulating ERβ.Journal of translational medicine · 2020Article
- PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer.Journal of experimental & clinical cancer research : CR · 2019Article
- PES1 In Liver Cancer: A Prognostic Biomarker With Tumorigenic Roles.Cancer management and research · 2019Article
- Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.Oncotarget · 2016Article
- Estrogen receptor β sustains epithelial differentiation by regulating prolyl hydroxylase 2 transcription.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Chaihu-Shugan-San administration ameliorates perimenopausal anxiety and depression in rats.PloS one · 2013Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alteration of the ERα/ERβ balance is a critical step in breast cancer development and progression, and selective restoration of the activity of estrogen receptors has been proposed as one of the major therapeutic approaches for breast cancer. In this issue of JCI, Cheng et al. show that, by differentially modulating the stability of ERα and ERβ, PES1 increases the ERα/ERβ ratio and triggers breast tumor growth. These findings highlight PES1 as a potential target for the treatment of breast cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.